PURPOSE: We investigated the efficacy of gefitinib re-challenge for the patients who
responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter …

Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …

Introduction Salvage treatment for acquired resistance to epidermal growth factor receptor
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …

Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …

Background: New therapeutic modalities are needed for non-small cell lung cancer
(NSCLC) patients whose tumors have become resistant to gefitinib. Patients and Methods …

Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …

Background: The optimal treatment for patients with progressive non-small cell lung cancer
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …

Background Gefitinib treatment results in considerably better progression-free survival
compared with that of platinum doublets in the first line treatment of nonsmall-cell lung …

PURPOSE: Gefitinib is a valid second-line therapy for previously treated non-small cell lung
cancer (NSCLC) patients. The influences of various chemotherapy regimens and EGFR …

Gefitinib has shown activity in the treatment of non-small-cell lung cancer (NSCLC) patients
who failed previous platinum-based combination chemotherapy and/or taxane treatment …